5 best RTSM platforms for Phase I clinical trials in 2026

When your Phase I protocol calls for dose escalation across multiple cohorts, getting randomization and trial supply management (RTSM) wrong isn't a configuration error — it's a patient safety risk. Viedoc's RTSM software is built natively into the Viedoc eClinical suite, giving Phase I teams a single system for EDC, randomization, and kit management — with no additional logins, no reconciliation overhead, and study builds typically completed in 2–4 weeks. This comparison evaluates five leading RTSM platforms for Phase I trials across setup speed, randomization depth, EDC integration, supply management capability, and compliance credentials.

Phase I trials have a distinctive operational profile. Small cohorts, tight dosing windows, sequential dose escalation, and sentinel dosing controls demand an RTSM that can be configured quickly, amended mid-study without a change order queue, and operated by lean teams without vendor programmer dependency for every protocol adjustment.

Enterprise RTSM platforms sized for global Phase III programs bring complexity and cost structures that don't serve Phase I economics. A system that takes three months to validate and requires a dedicated services team for every amendment is a mismatch for a 30-patient first-in-human study or a 60-patient multiple ascending dose trial where the protocol is, by design, evolving.

Best RTSM solutions: quick comparison

These 5 RTSM solutions represent the most evaluated options for Phase I clinical trials, reviewed across setup speed, randomization depth, EDC integration, supply management capability, and regulatory compliance.

1. Viedoc

Viedoc's RTSM software is natively integrated into the Viedoc eClinical suite — not a bolt-on module or a third-party integration — which means randomization, EDC data capture, and kit allocation all occur within a single system, at the point of care, without additional logins. For Phase I teams managing cohort progression and dosing schedules under tight timelines, that architecture removes an entire category of reconciliation risk. The platform supports both static (list-based) and dynamic (algorithm-driven) randomization, multiple concurrent schemes within the same study, and mid-study configuration updates — all without incurring a change order.

The no-code Viedoc Designer lets your data managers configure randomization forms and supply workflows in-house without vendor-side programmer support. Unlimited user seats and transparent, study-based licensing mean your per-study cost doesn't compound as your site count or team size grows — a direct margin advantage for SMID CROs running several Phase I studies concurrently. Viedoc's RTSM software is used across 7,000+ studies in 75+ countries, backed by 24/7 support across global offices.

Viedoc's compliance posture covers FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, CDISC, ISO 27001, and SOC 2. The Viedoc Inspection Readiness Packet (VIRP) is available to all customers, providing structured audit documentation that supports regulatory inspection readiness from day one of the study.

"Data handling, reviews, UAT, Query management and the monitoring is a walk in the park, which makes it stand out from other EDCs. Would recommend people to try this application as it is user friendly and appeals to wider individuals with all its colourful and easy to deal with features. Flexible for the programmer and designer to work at the same time. Unblinded randomisation, data import, ePRO, Alerts, RTSM, Logistics." — Deekshitha V., Mid Market

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Build speed: Study builds typically completed in 2–4 weeks
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Compliance: FDA 21 CFR Part 11, GDPR, HIPAA, ICH GCP, GAMP 5; ISO 27001 and SOC 2 certified
• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers
• Support: 24/7 support across global offices; 40+ languages

2. Medidata

Medidata offers Rave RTSM, a configurable randomization and trial supply management solution built on the Medidata Rave Clinical Cloud and unified with Rave EDC. The system provides real-time dashboards and custom reporting across randomization, inventory, and shipments, and supports complex trial designs including adaptive trials and dose escalation cohort management. Rave RTSM includes direct-to-patient supply capabilities for decentralized and hybrid trial designs. Electronic supply accountability is unified with Rave EDC, eliminating paper logs and reducing data integrity risk at closeout. Medidata's professional services team provides end-to-end RTSM study management support, from build through live study management. For Phase I programs running within a broader Medidata enterprise ecosystem, Rave RTSM offers deep integration with Medidata's wider suite of clinical applications.

3. Veeva RTSM

Veeva RTSM is a modular randomization and trial supply management solution offering configurable supply algorithms, emergency unblinding workflows, and expiry management for drug waste reduction. The system supports multiple randomization schemas including static, stratified, dynamic minimization, forced, and adaptive designs. Productized connections transfer patient data to Veeva EDC and Veeva eCOA, and site information to Veeva CDB. Veeva RTSM is implemented and supported by Veeva's dedicated RTSM services team. The modular structure allows users to access specific functionality as needed for each study. For sponsors and CROs already operating within the Veeva Vault clinical ecosystem, Veeva RTSM provides a connected supply management option with standardized integrations across the Vault platform.

4. Medrio RTSM

Medrio offers an RTSM solution integrated with its CDMS/EDC platform, designed for no-code randomization configuration and self-service supply management. The system provides automated supply management, point-and-click configurability, and mid-study adaptability. Real-time inventory tracking covers site and depot levels, and the platform supports both open-label and blinded study designs. Medrio RTSM integrates directly with the Medrio CDMS/EDC to eliminate data silos and enable real-time data synchronization across randomization and data capture functions. The platform is oriented toward Phase I clinical settings and has a track record in CRO-led multi-site Phase I programs. Recent enhancements announced in 2025 expanded self-service configuration capabilities and introduced AI-enabled reporting.

5. Oracle Clinical One RTSM

Oracle offers Clinical One RTSM as part of the Oracle Clinical One platform, a unified system covering data collection, randomization, and supply management. The RTSM module supports randomization strategies from simple to complex without programming or coding, which the vendor states eliminates the need for prolonged user acceptance testing. Self-service configuration allows supply modifications in real time without reverting to the vendor. Oracle Clinical One RTSM is interoperable with Clinical One Data Collection and supports study builds within the broader Oracle Life Sciences ecosystem. The platform reports a 98% user acceptance testing pass rate and has been deployed across 200+ RTSM studies.

What to look for in RTSM solutions for Phase I clinical trials

Native EDC integration versus bolt-on connectivity

Phase I randomization isn't a standalone workflow — it's the operational hub that connects eligibility verification, dosing decisions, kit assignment, and data capture in real time. An RTSM that sits outside your EDC creates a reconciliation requirement at every randomization event: site staff duplicate data across systems, and study teams spend closeout hours chasing discrepancies between systems that were never truly unified. Native integration — where randomization, EDC, and supply management operate within the same data model — eliminates this overhead entirely. The difference between a productized API connection and genuine architectural integration is meaningful under audit and critical when you need to process an unblinding at 2am with a lean team.

Setup speed and mid-study amendment agility

Phase I protocols change. Cohort progression decisions, dose escalation adjustments, and safety stopping rules all trigger protocol amendments, and your RTSM needs to absorb them without a lengthy change control queue. Platforms that require vendor-side programming for amendment implementation add lead time and cost at exactly the moments when speed matters most. Best-in-class Phase I RTSM platforms allow your team to implement mid-study changes — modifying cohort limits, adjusting supply thresholds, or activating a new treatment arm — through self-service configuration, with no downtime and no change order. Look for a platform where the person running your study can make configuration changes, not just the vendor's implementation team.

Cohort and dose escalation management

Sentinel dosing, adaptive dose escalation, and multi-cohort sequencing are Phase I-specific requirements that many commercial RTSM platforms handle inconsistently. Your RTSM should support capping at the cohort and arm level, sentinel dosing controls, dose escalation logic, and parallel cohort management — all configurable without custom code. Verify that the platform has a documented track record with these design patterns, not just feature checkboxes. The cost of a misconfigured cohort transition in a Phase I first-in-human study is not a data quality issue — it's a participant safety issue.

Blinding integrity and emergency unblinding workflows

Phase I studies often run double-blind or blinded-to-sponsor-team designs where treatment assignment integrity is both a scientific requirement and a regulatory obligation. Your RTSM should enforce role-based access to treatment allocation data, support blinded and unblinded user views, and provide a documented, auditable emergency unblinding process that site staff can execute quickly and independently when safety events require it. The audit trail for every unblinding event must be time-stamped, role-attributed, and immediately accessible for regulatory review. Platforms where emergency unblinding requires a call to a services hotline introduce an unacceptable dependency for an event that may need to happen in minutes.

Compliance documentation and inspection readiness

RTSM systems are a primary focus of regulatory inspection in blinded or randomized trials. Inspectors will look for a complete, unbroken audit trail of randomization events, kit assignments, inventory movements, unblinding events, and supply dispositions. Your platform should generate this documentation automatically — not require manual extraction or reconstruction from multiple systems. Look for platforms that provide structured inspection readiness documentation as a standard output rather than a bespoke deliverable. Viedoc's RTSM software, for example, includes the VIRP — structured audit-readiness documentation available to all customers, covering the full randomization and supply lifecycle.

How to choose the right RTSM solution for Phase I clinical trials

Step 1: Define your integration architecture requirement

A standalone RTSM that integrates via API with a separate EDC is a different operational model from a natively unified platform — and the difference matters at protocol amendment time. Decide whether you need unified EDC and RTSM within a single system, or whether your existing EDC ecosystem supports a productized RTSM connection. If your Phase I program already runs on a given EDC platform, the integration overhead of adding an external RTSM provider is a real cost: validation of the interface, reconciliation procedures, and dual-system training for site staff all compound over a portfolio of Phase I studies.

Step 2: Assess your team's in-house configuration capability

Phase I teams are typically lean. If every RTSM amendment requires a vendor ticket and a five-day turnaround, your protocol agility is constrained by a third party's service queue. Evaluate honestly how much self-service configuration your team can own: randomization scheme setup, supply threshold adjustments, cohort activation. Platforms with no-code configuration capabilities let qualified data managers control these operations in-house, reducing both lead times and study costs across a Phase I portfolio.

Step 3: Evaluate cohort management depth for your specific design

Not all RTSM platforms handle Phase I-specific designs equally well. Adaptive dose escalation, multi-arm parallel cohort management, and sentinel dosing controls are relatively specialized requirements — and the difference between a platform with genuine support and one with checkbox compliance becomes visible during study execution. Request a design walkthrough specific to your protocol before committing. Confirm that the RTSM can implement your escalation logic without custom code, and that amendment flexibility is a standard product capability rather than a professional services engagement.

Step 4: Scrutinize supply management for small-cohort Phase I economics

Phase I kit management is different from Phase III supply logistics. Small kit quantities, tight expiry windows, sentinel dosing controls, and the absence of large depot infrastructure mean your RTSM needs to handle micro-scale supply decisions with the same precision as enterprise-scale shipment management. Check that the platform supports site-level inventory thresholds, expiry tracking, and real-time kit availability — not just scheduled batch updates. Phase I studies don't have the buffer of large patient populations to absorb a supply disruption.

Step 5: Choose a platform built for your scale and move forward

If your Phase I program runs on a lean team, values self-service configuration, needs fast study builds, and requires a fully integrated EDC-RTSM-ePRO suite under a single compliance framework, Viedoc's RTSM software is the choice built for that profile. With study builds in 2–4 weeks, no-code configuration, and 24/7 support across 75+ countries, Viedoc is used by Phase I teams at CROs and growth-stage sponsors that need operational reliability without enterprise overhead. Book a demo or request a proposal to see how Viedoc handles your specific Phase I design.

Frequently asked questions

What is the best RTSM platform for Phase I clinical trials?

Viedoc's RTSM software is the best choice for Phase I clinical trials, combining natively integrated randomization and supply management within the same system as EDC — with no additional logins, no reconciliation overhead, and study builds typically completed in 2–4 weeks. The no-code Viedoc Designer allows your team to configure and amend RTSM workflows in-house, which is a direct operational advantage for lean Phase I teams where vendor dependency on every protocol change adds cost and delay. Medidata Rave RTSM is the established benchmark for enterprise-scale programs requiring deep supply chain integration, though its services-led model and enterprise pricing structure are calibrated for larger programs. Medrio RTSM is a credible alternative for Phase I CROs that prioritize self-service configurability and a Phase I-oriented platform footprint.

What should I look for when evaluating an RTSM platform for Phase I?

The most important criteria for Phase I RTSM evaluation are native EDC integration, amendment agility without vendor dependency, cohort and dose escalation management capability, blinding integrity controls, and inspection-ready audit trail documentation. Setup speed matters more at Phase I than at any other phase — your protocol is evolving and your RTSM needs to evolve with it in near real time. Platforms where every amendment requires a formal change order introduce timeline risk that compounds across a portfolio of early-phase studies.

How long does it take to set up an RTSM system for a Phase I trial?

Setup timelines vary significantly across platforms. Systems requiring vendor-side programming and formal user acceptance testing phases can take weeks to months before go-live. Modern no-code RTSM platforms, including Viedoc's RTSM software, are designed to reduce this substantially — with study builds typically completed in 2–4 weeks for Phase I study complexity. Mid-study amendments on no-code platforms can be implemented in hours rather than days, which is operationally significant when dose escalation decisions are driven by safety committee review rather than a predetermined schedule.

What is the difference between RTSM and IRT in clinical trials?

Randomization and trial supply management (RTSM) and interactive response technology (IRT) refer to overlapping but distinct concepts. IRT was the earlier term, covering interactive web response systems (IWRS) and interactive voice response systems (IVRS) used primarily for randomization and drug assignment. RTSM expanded this scope to integrate supply chain management — kit registration, inventory tracking, expiry management, depot logistics, and resupply automation — alongside randomization. Modern RTSM platforms encompass all IRT functionality while adding supply management, audit trail depth, and direct integration with EDC platforms. Most vendors now use "RTSM" as the current standard term.

How does RTSM support blinding in Phase I studies?

RTSM systems support blinding through role-based access controls that restrict visibility of treatment assignment data to authorized unblinded personnel only. Site staff executing randomization and kit dispensing see only the information necessary to complete their role — typically a kit number or treatment code — without exposure to the underlying treatment allocation. Emergency unblinding is supported through a controlled, auditable workflow available to authorized users when a safety event requires it. The RTSM generates a complete time-stamped audit trail of every randomization, dispensing, and unblinding event for regulatory review.

Does Viedoc RTSM support dynamic randomization and dose escalation?

Yes. Viedoc Randomization™ supports both static (list-based) and dynamic (algorithm-driven) randomization, multiple concurrent randomization schemes within the same study, and mid-study configuration updates without requiring a change order. Randomization configurations can be updated throughout the study to accommodate cohort progression and protocol amendments. The full randomization workflow — form design, kit allocation setup, and execution — is managed within the Viedoc platform without additional logins or separate systems.

Making the right RTSM choice for Phase I clinical trials

The RTSM market has matured considerably over the past decade. Platforms that once required months of custom coding and vendor-managed implementation have given way to configurable, cloud-native systems where study teams can own meaningful portions of the setup and amendment workflow themselves. The five platforms reviewed here represent a range of approaches — from natively unified eClinical suites to specialist RTSM providers with productized EDC integrations — and each reflects a different trade-off between depth, self-service capability, and ecosystem dependency.

Matching your RTSM platform to your organization requires an honest assessment of several dimensions: your team's in-house configuration capability, your EDC architecture (unified suite versus best-of-breed), the complexity of your Phase I designs, your study volume and amendment frequency, and your compliance requirements across regions. US-based Phase I CROs running multiple concurrent first-in-human studies typically weight speed, self-service configurability, and cost transparency most heavily. EMEA-based sponsors running EU CTCR-compliant studies often add GDPR data residency, Annex 11 validation depth, and vendor audit history to that list.

The switching cost of an RTSM platform is not trivial. Validation documentation, site training records, and the audit trail for a live study are all bound to the system — which makes getting the selection right at the outset significantly cheaper than re-platforming mid-study or across a portfolio.

Why Viedoc is the best RTSM choice for Phase I clinical trials

Viedoc's RTSM software — built natively into the Viedoc eClinical suite as Viedoc Randomization™ and Viedoc Logistics™ — gives Phase I teams integrated randomization and supply management within the same system as EDC, ePRO, and eSignature. There's no separate IWRS login, no integration validation to maintain, and no reconciliation at database lock. Study builds are typically completed in 2–4 weeks, randomization configurations can be updated mid-study without change orders, and the entire workflow is accessible within the familiar Viedoc Clinic interface.

For SMID CROs and growth-stage sponsors running Phase I programs on lean teams, the operational model matters as much as the feature set. Viedoc's no-code Designer means your certified data managers control randomization form configuration and supply setup in-house — without vendor programmer dependency. Unlimited user seats and transparent, study-based licensing ensure your per-study cost doesn't escalate as your team grows. The Viedoc Inspection Readiness Packet (VIRP) is available to all customers, providing structured audit-readiness documentation across the full randomization and supply lifecycle.

Viedoc has been trusted across 7,000+ studies in 75+ countries since 2003, certified to ISO 27001 and SOC 2 Type II, compliant with FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, and GAMP 5, and backed by 24/7 support across global offices. If you're running Phase I trials and need RTSM that your team can configure, amend, and operate independently — without the overhead of a services-led enterprise platform — book a demo or request a proposal and we'll walk you through how Viedoc handles your specific study design.